Clinical Trials
The following trials are presently being conducted by Dr. Boeckh’s Group.
- Dried Blood Spot Testing of CMV Detection in HCT Recipients
- Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis (GRAIL Phase 3)
- A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects
- Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects
- Pharmacokinetics of Sovotrimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients
Trials that have ended recently (link to see status/results)
- The Safety and Efficacy of Therapeutic CMV vaccine ASP0113
- A Phase 3 Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Letermovir (LET) Prophylaxis When Extended From 100 Days to 200 Days Post-transplant in Cytomegalovirus (CMV) Seropositive Recipients (R+) of an Allogenic Hematopoietic Stem Cell Transplant (HSCT)
- A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Clinical Outcomes, Antiviral Activity, Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics/Pharmacodynamics of JNJ-53718678 in Adult and Adolescent Hematopoietic Stem Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
A Boeckh Group clinical trial coordinator at her desk
Caren Brinkema
A Boeckh Group clinical trial coordinator observes a study participant completing a nasal swab
A Boeckh Group team member prepares sample kits for a study.
Fred Hutchinson Cancer Center | 1100 Fairview Ave. N., Seattle, WA 98109
© 2025 Fred Hutchinson Cancer Center, a 501(c)(3) nonprofit organization.
© 2025 Fred Hutchinson Cancer Center, a 501(c)(3) nonprofit organization.